Citadel Advisors LLC decreased its position in BIO-TECHNE Corp (NASDAQ:TECH) by 24.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,243 shares of the biotechnology company’s stock after selling 12,598 shares during the quarter. Citadel Advisors LLC owned 0.10% of BIO-TECHNE worth $8,010,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. BlackRock Inc. grew its position in BIO-TECHNE by 2.5% in the second quarter. BlackRock Inc. now owns 3,776,455 shares of the biotechnology company’s stock valued at $558,726,000 after acquiring an additional 91,519 shares in the last quarter. Schroder Investment Management Group grew its position in BIO-TECHNE by 975.1% in the second quarter. Schroder Investment Management Group now owns 2,211,502 shares of the biotechnology company’s stock valued at $85,499,000 after acquiring an additional 2,005,804 shares in the last quarter. Janus Henderson Group PLC grew its position in BIO-TECHNE by 5.8% in the second quarter. Janus Henderson Group PLC now owns 1,393,027 shares of the biotechnology company’s stock valued at $206,098,000 after acquiring an additional 76,538 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in BIO-TECHNE by 13.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 677,968 shares of the biotechnology company’s stock valued at $138,381,000 after acquiring an additional 79,963 shares in the last quarter. Finally, First Trust Advisors LP grew its position in BIO-TECHNE by 41.1% in the third quarter. First Trust Advisors LP now owns 672,964 shares of the biotechnology company’s stock valued at $137,359,000 after acquiring an additional 195,950 shares in the last quarter. 93.90% of the stock is owned by institutional investors.

Several brokerages have issued reports on TECH. Zacks Investment Research raised shares of BIO-TECHNE from a “sell” rating to a “hold” rating in a research report on Wednesday. Goldman Sachs Group set a $165.00 price objective on shares of BIO-TECHNE and gave the company a “hold” rating in a research report on Friday, November 30th. Craig Hallum downgraded shares of BIO-TECHNE from a “buy” rating to a “hold” rating and lowered their price objective for the company from $215.00 to $154.00 in a research report on Wednesday, October 31st. BidaskClub raised shares of BIO-TECHNE from a “hold” rating to a “buy” rating in a research report on Tuesday, October 30th. Finally, Argus increased their target price on BIO-TECHNE from $210.00 to $230.00 and gave the company a “buy” rating in a research note on Tuesday, October 2nd. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $181.00.

BIO-TECHNE stock opened at $160.39 on Thursday. The company has a market cap of $6.10 billion, a PE ratio of 39.41, a price-to-earnings-growth ratio of 2.89 and a beta of 1.05. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.59 and a quick ratio of 3.50. BIO-TECHNE Corp has a 52 week low of $125.84 and a 52 week high of $206.04.

BIO-TECHNE (NASDAQ:TECH) last released its earnings results on Tuesday, October 30th. The biotechnology company reported $0.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.03. The company had revenue of $163.00 million during the quarter, compared to analysts’ expectations of $162.34 million. BIO-TECHNE had a return on equity of 14.09% and a net margin of 19.19%. The business’s revenue was up 12.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.90 EPS. As a group, analysts forecast that BIO-TECHNE Corp will post 3.79 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, November 23rd. Stockholders of record on Friday, November 9th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.80%. The ex-dividend date was Thursday, November 8th. BIO-TECHNE’s dividend payout ratio (DPR) is currently 31.45%.

COPYRIGHT VIOLATION WARNING: “Citadel Advisors LLC Sells 12,598 Shares of BIO-TECHNE Corp (TECH)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/citadel-advisors-llc-sells-12598-shares-of-bio-techne-corp-tech/2664085.html.

About BIO-TECHNE

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Featured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BIO-TECHNE Corp (NASDAQ:TECH).

Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.